The Infinite Brief

The deal for the drug, which is being investigated as a potential treatment for inflammatory diseases, is with Spanish pharmaceutical company Almirall.

More than 80% of their customers have agreed to their data being used by the company for research and by scientists trying to understand the causes of diseases and how best to treat them.

As 23andMe’s genetic database grows – it has doubled in the last couple of years – it will become more likely to yield medically useful information.